Achieve Life Sciences Q2 loss per share misses estimates

Achieve Life Sciences

07/08/2025 12:54

Overview

Achieve submitted NDA for cytisinicline to FDA, marking a major milestone

Co raised $49.3 mln in public offering to advance cytisinicline

Q2 loss per share misses estimates; net loss and loss from operations beat estimates, per LSEG data

Outlook

Achieve expects funding to support operations into H2 2026

Result Drivers

NDA SUBMISSION - Achieve submitted NDA for cytisinicline to FDA, marking a major milestone

PARTNERSHIP - Co partnered with Omnicom to streamline cytisinicline launch, aiming to reduce costs and optimize performance

PUBLIC OFFERING - Achieve raised $49.3 mln in public offering to support cytisinicline advancement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Miss
-$0.37
-$0.36 (5 Analysts)
Q2 Net Income
Beat
-$12.72 mln
-$12.90 mln (5 Analysts)
Q2 Income From Operations
Beat
-$12.56 mln
-$13.10 mln (5 Analysts)
Q2 Operating Expenses
$12.56 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Achieve Life Sciences Inc is $14.00, about 81.1% above its August 6 closing price of $2.64

Press Release: ID:nGNX7YwnfP

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)